Eli Lilly and Company $LLY Holdings Decreased by Northwest Wealth Management LLC

Key Points

• Northwest Wealth Management LLC reduced its stake in Eli Lilly and Company by 30.5% in Q2, now owning 851 shares valued at approximately $663,000.
• Several large investors increased their holdings in Eli Lilly, with Brighton Jones LLC raising its stake by 22.0% in the previous quarter.
• Recent earnings reports show Eli Lilly achieved $6.31 EPS, exceeding analysts' expectations, with revenue rising 37.6% year-over-year to $15.56 billion.

Northwest Wealth Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 30.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 851 shares of the company's stock after selling 373 shares during the period. Northwest Wealth Management LLC's holdings in Eli Lilly and Company were worth $663,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Douglas Lane & Associates LLC increased its position in shares of Eli Lilly and Company by 5.7% during the 1st quarter. Douglas Lane & Associates LLC now owns 2,985 shares of the company's stock valued at $2,465,000 after purchasing an additional 162 shares during the period. Future Financial Wealth Managment LLC raised its stake in shares of Eli Lilly and Company by 3.3% in the 1st quarter. Future Financial Wealth Managment LLC now owns 1,578 shares of the company's stock worth $1,303,000 after buying an additional 50 shares in the last quarter. Finally, Baker Tilly Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 5.9% in the first quarter. Baker Tilly Wealth Management LLC now owns 1,447 shares of the company's stock valued at $1,195,000 after buying an additional 80 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LLY. Guggenheim lowered their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Finally, Cantor Fitzgerald dropped their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $725.54 on Tuesday. The company has a market capitalization of $686.69 billion, a PE ratio of 47.42, a PEG ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company's 50 day moving average price is $733.42 and its 200 day moving average price is $765.98. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 EPS. The company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.